TY - JOUR T1 - Sex-specific trajectories of molecular cardiometabolic trait concentrations through childhood, adolescence and young adulthood: a cohort study JF - medRxiv DO - 10.1101/2021.07.28.21261181 SP - 2021.07.28.21261181 AU - Linda M. O’Keeffe AU - Kate Tilling AU - Joshua A. Bell AU - Matthew A. Lee AU - Deborah A. Lawlor AU - George Davey Smith AU - Patricia M. Kearney Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/30/2021.07.28.21261181.abstract N2 - Background Causal risk factors and predictive biomarkers for cardiometabolic diseases are increasingly being identified from comprehensive metabolomic profiling in epidemiological studies. The changes which typically occur in molecular cardiometabolic traits across early life are not well characterised.Methods We quantified sex-specific trajectories of 148 metabolic trait concentrations including various lipoprotein subclasses from age 7y to 25y. Data were from offspring of the Avon Longitudinal Study of Parents and Children birth cohort study. Outcomes included concentrations of 148 traits quantified using nuclear magnetic resonance spectroscopy measured at 7y, 15y, 18y and 25y. Sex-specific trajectories of each trait concentration were modelled using linear spline multilevel models with robust standard errors.Findings 7,065-7,626 participants (11,702-14,797 repeated measures) were included in analyses. Females had higher very-low-density lipoprotein (VLDL) particle concentrations at 7y. VLDL particle concentrations decreased from 7y to 25y with larger decreases in females, leading to lower VLDL particle concentrations at 25y in females. For example, females had 0.25 SD (95% Confidence Interval (CI), 0.20, 0.31) higher very small VLDL particle concentration at 7y; mean levels decreased by 0.06 SDs (95% CI, −0.01, 0.13) in males and 0.85 SDs (95% CI, 0.79, 0.90) in females from 7y to 25y leading to 0.42 SD (95% CI, 0.35, 0.48) lower very small VLDL particle concentrations in females at 25y. Females also had higher low-density lipoprotein (LDL) particle concentrations at 7y; these increased from 7y to 25y in both sexes and increases were larger among males. By age 25y, LDL particle concentrations remained higher in females but the sex difference was smaller than in early childhood. Females had lower high-density lipoprotein (HDL) particle concentrations at 7y. HDL particle concentrations increased from 7y to 25y with larger increases among females leading to higher HDL particle concentrations in females at 25y.Interpretation Childhood and adolescence are important periods for the emergence of sex differences in atherogenic lipids and predictive biomarkers for cardiometabolic disease, mostly to the detriment of males.Funding Wellcome Trust, Medical Research Council UK, Health Research Board, IrelandEvidence before this study Causal risk factors and novel predictive biomarkers for cardiometabolic diseases are increasingly being identified from the recent application of comprehensive metabolomic profiling in epidemiological studies but the change which typically occur in these traits across childhood, adolescence and early adulthood is not well u understood.Added value of this study In this prospective cohort study with repeat assessments of 148 molecular cardiometabolic traits from comprehensive metabolomic profiling at age 7y, 15y, 18y and 25y, we demonstrate that marked change in levels of causal risk factors and novel predictive biomarkers for cardiometabolic diseases occur from childhood to early adulthood. In addition, our findings suggest that childhood and adolescence are an important life stage for the development of sex differences in atherogenic lipids and predictive biomarkers for cardiometabolic disease, mostly to the detriment of males.Implications of all the available evidence Findings suggest that cardiometabolic disease prevention targeting childhood and adolescence should be prioritised for both lifelong cardiometabolic disease prevention and sex differences in cardiometabolic risk to the disadvantage of males across the life course.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe UK Medical Research Council and Wellcome (Grant ref: 102215/2/13/2) and the University of Bristol provide core support for ALSPAC. LMOK is supported by a Health Research Board (HRB) of Ireland Emerging Investigator Award (EIA-FA-2019-007 SCaRLeT) and a UK Medical Research Council Population Health Scientist fellowship (MR/M014509/1). GDS, JAB, and DAL work in a unit that receives funds from the UK Medical Research Council (grants MC_UU_00011/1, MC_UU_00011/3, MC_UU_00011/6). DAL is BHF Chair of Cardiovascular Science and Clinical Epidemiology (CH/F/20/90003) and a National Institute of Health Research Senior Investigatory (NF-0616-10102). These funding sources had no role in the design and conduct of this study. This publication is the work of the authors and LMOK will serve as guarantor for the contents of this paper.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for the study was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon submission and approval of a proposal to the ALSPAC Executive. Further information is available at http://www.bristol.ac.uk/alspac/researchers/our-data/. ER -